Insmed Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Insmed stock.
View analyst ratings for Insmed or view top-rated stocks.

Wall Street analysts have given Insmed a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Insmed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Insmed.

Insmed Incorporated (NASDAQ:INSM) announced its earnings results on Thursday, February, 25th. The biopharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by $0.33. The biopharmaceutical company had revenue of $41.42 million for the quarter, compared to the consensus estimate of $41.44 million. Insmed had a negative trailing twelve-month return on equity of 79.58% and a negative net margin of 145.14%. The business's revenue was down 9.4% compared to the same quarter last year. During the same period last year, the business posted ($0.59) EPS.
View Insmed's earnings history.

Insmed's stock was trading at $21.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INSM stock has increased by 79.4% and is now trading at $38.13.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued 1-year price targets for Insmed's shares. Their forecasts range from $44.00 to $60.00. On average, they expect Insmed's share price to reach $53.86 in the next year. This suggests a possible upside of 41.2% from the stock's current price.
View analysts' price targets for Insmed or view top-rated stocks among Wall Street analysts.

14 employees have rated Insmed CEO Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among Insmed's employees.

Some companies that are related to Insmed include CureVac (CVAC), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Zai Lab (ZLAB), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), Mirati Therapeutics (MRTX), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Ascendis Pharma A/S (ASND) and ACADIA Pharmaceuticals (ACAD).
View all of INSM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed's stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.48%), Janus Henderson Group PLC (5.72%), William Blair Investment Management LLC (3.64%), Baker BROS. Advisors LP (2.12%), Artisan Partners Limited Partnership (2.01%) and Lord Abbett & CO. LLC (1.97%). Company insiders that own Insmed stock include Alfred Altomari, Christine A Pellizzari, Donald J Hayden Jr, John Goll, John Soriano, Melvin Md Sharoky, Orlov S Nicole Schaeffer and William Lewis.
View institutional ownership trends for Insmed.

INSM stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Janus Henderson Group PLC, Alliancebernstein L.P., Rice Hall James & Associates LLC, Baker BROS. Advisors LP, Hudson Bay Capital Management LP, GSA Capital Partners LLP, and C WorldWide Group Holding A S. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari, Christine A Pellizzari, John Soriano, Melvin Md Sharoky, Orlov S Nicole Schaeffer, and William Lewis.
View insider buying and selling activity for Insmed or view top insider-selling stocks.

INSM stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Artisan Partners Limited Partnership, Norges Bank, Lord Abbett & CO. LLC, Hood River Capital Management LLC, Frontier Capital Management Co. LLC, Silverarc Capital Management LLC, and GW&K Investment Management LLC.
View insider buying and selling activity for Insmed or or view top insider-buying stocks.

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INSM stock can currently be purchased for approximately $38.13.

Insmed has a market capitalization of $3.93 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-254,340,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis.

Insmed employs 373 workers across the globe.

The official website for Insmed is www.insmed.com.

Insmed is headquartered at 700 US Highway 202/206, Bridgewater NJ, 08807.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]